By controlling blood pressure, quitting smoking, and dynamically monitoring MALAT1 and NLRP3 indicators, T2DM patients can delay the occurrence of lower extremity atherosclerosis, prevent it from developing into lower extremity vascular occlusion or diabetes foot and other serious diseases, improve the prognosis and quality of life of patients, and at the same time, it is convenient for doctors to early identify high-risk patients with diabetes who may have LEAD, and develop diagnosis and treatment measures for them. The gene discussed is NLRP3; the disease is atherosclerosis.